CDI Labs

Autoantibodies have long been associated solely with autoimmune disease, but that may be changing.
In a recent talk hosted by Tyler Hulett, Chief Scientific Officer CDI Labs, he shared insights that are reshaping our understanding of these powerful immune markers. Far from being rare, autoantibodies are common, complex, and individually unique acting as both storytellers of past exposures and drivers of future disease.
Discover how advances in proteome-array technology and deep immune-profiling are unlocking new diagnostics, biomarkers, and therapeutic pathways in chronic illness and precision medicine.
Looking to explore your own immune fingerprint? Connect with us at [email protected]. Read full blog below.

Autoantibodies have long been associated solely with autoimmune disease, but that may be changing. | CDI Labs Autoantibodies have long been associated solely with autoimmune disease, but that may be changing. In a recent talk hosted by Tyler Hulett, Chief Scientific Officer CDI Labs, he shared insights that are reshaping our understanding of these powerful immune markers. Far from being rare, autoantibodies...

PRESS RELEASE: We’re excited to announce the launch of our comprehensive Pan-isotype Profiling and Analysis platform! This cutting-edge solution enables researchers to explore all isotypes and subclasses, including IgA, IgD, IgE, IgG, and IgM, providing deeper insights into immune responses. With our advanced ™ and ® platforms, you can now conduct thorough pan-isotype profiling across thousands of human proteins. Whether you're investigating inflammatory conditions, autoimmune responses, or overall immune state, our innovative approach allows for a comprehensive and detailed analysis.

Dr. Barney Saunders states,"In the past, autoantibody discovery and profiling has often been limited to pan-IgG analysis, but each isotype and subclass plays a distinct role in humoral immunity... While earlier limitations in technology made this difficult, our new pan-isotype and subclass analysis capabilities now make it possible to explore these differences in far greater depth."

Learn more about Pan-isotype Profiling here:
https://cdilabs.com/services/pan-isotype-profiling

Read press release here:
https://cdilabs.com/news-events/cdi-labs-launches-pan-isotype-analysis

In a paper published in Frontiers in Immunology, Lixin Zhang and colleagues at the University of Pittsburgh School of Medicine explore the complex role of B lymphocytes in the ovarian tumor microenvironment. Utilizing our cutting-edge human proteome microarray, the researchers profiled over 21,000 proteins to identify critical antigens recognized by antibody-secreting B cells in cases of epithelial ovarian cancer (EOC). Notably, they found anti-CCDC155 circulating IgG antibodies in a substantial proportion of EOC patients’ sera, suggesting potential biomarkers for patient prognosis. This collaboration between HuProt technology and ovarian cancer research paves the way for future investigations into B cell biology, target antigen recognition, and the role of Epstein-Barr virus (EBV) proteins in shaping the tumor microenvironment.

View / download paper here,
https://www.cdilabs.com/content/publications/pos-characterization-of-latently-infected-ebv-antibody-secreting-b-cells-zhang

PRESS RELEASE: We are thrilled to announce the launch of our innovative Peptide Hormone PhIP-Seq library, a groundbreaking advancement in identifying hormone-specific autoantibodies. This cutting-edge technology combines phage display with next-gen sequencing, enabling high-throughput screening and detailed epitope mapping of autoantibody responses against a diverse panel of human peptide hormones. Understanding the role of these autoantibodies is crucial in unveiling the complexities of hormonal dysregulation and its connection to diseases like obesity, diabetes, and various mood disorders. Our comprehensive library allows researchers to explore the immunological aspects of endocrine function in new and profound ways.

"Our new Peptide Hormone Library provides researchers with a cost-effective and high-throughput tool to interrogate these autoantibody responses," says CEO Dr. Barney Saunders.

More info here,
https://www.cdilabs.ca/services/peptide-hormone-phip-seq

Press release here,
https://www.cdilabs.com/news-events/cdi-labs-canada-launches-peptide-hormone-phip-seq